LY-CoV555 COVID-19 Description
LY-CoV555 is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19.
LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and tested by the scientists at the NIAID Vaccine Research Center.
LY-CoV555 COVID-19 Indication
LY-CoV555 is indicated to prevent or mitigate the progression of COVID-19 infection caused by SARS-CoV-2 virus.
LY-CoV555 COVID-19 News
August 3, 2020 - Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
LY-CoV555 COVID-19 Clinical Trials
Clinical Trial NCT04411628: A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
- The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19.
- Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.
Clinical Trial NCT04427501: A Study of LY3819253 (LY-CoV555) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)
- The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19.
- LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study.
- Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.